ACTIV-6: COVID-19 Study of Repurposed Medications - Arm C (Fluticasone) - Trial NCT05736874
Access comprehensive clinical trial information for NCT05736874 through Pure Global AI's free database. This Phase 3 trial is sponsored by Susanna Naggie, MD and is currently Completed. The study focuses on Covid19. Target enrollment is 1407 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Susanna Naggie, MD
Duke University
Timeline & Enrollment
Phase 3
Aug 06, 2021
May 18, 2022
Primary Outcome
Time to Sustained Recovery in Days
Summary
The purpose of this study is to evaluate the effectiveness of repurposed medications (study
 drug(s) in reducing symptoms of non-hospitalized participants with mild to moderate COVID-19.
 Participants will receive either study drug or placebo. They will self-report any new or
 worsening symptoms or medical events they may experience while taking study drug or placebo.
 This study is intended to be all remote with no in person visits, unless the study team feels
 it is in the best interest of a participant to see them in person.
 
 Prior and current drug arms are listed on clinicaltrials.gov and will be updated with the
 activation of any new drug arms. This protocol was originally registered under NCT04885530.
 Per recent guidance on reporting master protocol research programs (MPRPs), a separate record
 for Arm C was created.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05736874
Non-Device Trial